SpyGlass Pharma (SGP)
Develops sustained drug delivery for chronic eye conditions within established surgical workflows.
Something off on this page? Send us feedback.
Develops a non-bioerodible intraocular drug-delivery platform for chronic eye conditions. Its initial bimatoprost program, the BIM-IOL System, is in registrational Phase 3 trials and is designed for established surgical workflows.
Develops the SpyGlass Platform, a non-bioerodible intraocular drug-delivery technology designed to pair approved medicines with established eye-surgery workflows. Its initial focus is bimatoprost for chronic eye conditions, and the BIM-IOL System is tested alongside a commercial intraocular lens and twice-daily topical timolol. The platform originated at the University of Colorado Anschutz School of Medicine.
Clinical development is centered in Aliso Viejo, California, where the company is advancing two registrational Phase 3 BIM-IOL trials after completing first surgeries. The operating model depends on clinical execution, regulatory progress, and adoption within established surgical practice.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $234.2M · Total debt $1.6M · Total assets $243.4M · Shareholders' equity $232.4M
- Revenue
- $0
- Operating income
- −$22.0M
- Net income
- −$19.9M
No dividends on record.
| Institutions35 holders · as of Mar 31, 2026 | 75.83% | 25.35M shares | |
| Strategic holders1 holder · as of Feb 10, 2026 | 9.90% | 3.31M shares | |
| Otherremainder | 14.27% | 4.77M shares |
33.43M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 23.99% | 8.02M | 13Fas of Mar 31, 2026 |
Nea Management Company, LLCInstitution | 22.11% | 7.39M | 13Fas of Mar 31, 2026 |
Vensana Capital I GP, LLCStrategic | 9.90% | 3.31M | 13Dfiled Feb 10, 2026 ↗ |
Sands Capital Ventures, LLCInstitution | 7.48% | 2.50M | 13Fas of Mar 31, 2026 |
Samsara Biocapital, LLCInstitution | 6.31% | 2.11M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Glaukos
Long-duration implant and MIGS alternatives for glaucoma care
- AbbVie
Commercial bimatoprost intracameral implant for glaucoma care
- Alcon
MIGS and commercial IOL alternatives in cataract surgery
- Bausch + Lomb
Commercial enVista IOL alternatives in cataract surgery
- Johnson & Johnson
Commercial TECNIS IOL alternatives in cataract surgery
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SpyGlass Pharma | $28.35 | +5.55% | $945.5M | — | — | — | — |
| Glaukos | $179.40 | −0.04% | $10.59B | — | 1,400.9 | 17.3 | +49.5% |
| AbbVie | $262.35 | +0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Alcon | $72.47 | +0.33% | $35.23B | 55.6 | 18.8 | 3.3 | +7.5% |
| Bausch + Lomb | $18.00 | −0.06% | $6.43B | — | 18.1 | 1.2 | +9.1% |
| Johnson & Johnson | $275.41 | +0.06% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Median | 55.6 | 18.8 | 6.8 | +9.1% |